Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

BACKGROUND: TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monother...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiura, Kiyoaki, Seo, Yuki, Takahashi, Takayuki, Tokura, Hideyuki, Ito, Yasuhiro, Tanaka, Motomu, Kishida, Norihiro, Nishi, Yusuke, Onishi, Yoshihiko, Aoki, Hikaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058969/
https://www.ncbi.nlm.nih.gov/pubmed/33879100
http://dx.doi.org/10.1186/s12876-021-01771-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058969/
https://www.ncbi.nlm.nih.gov/pubmed/33879100
http://dx.doi.org/10.1186/s12876-021-01771-z

Ejemplares similares